IRIS
SCARPIGNATO, Carmelo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.720
AS - Asia 10.188
EU - Europa 5.896
SA - Sud America 1.571
AF - Africa 486
Continente sconosciuto - Info sul continente non disponibili 48
OC - Oceania 13
Totale 28.922
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.404
SG - Singapore 4.435
CN - Cina 3.181
IE - Irlanda 1.487
BR - Brasile 1.260
SE - Svezia 943
DE - Germania 879
FI - Finlandia 860
HK - Hong Kong 799
TR - Turchia 685
VN - Vietnam 629
NL - Olanda 436
IT - Italia 387
ZA - Sudafrica 357
UA - Ucraina 322
CA - Canada 214
GB - Regno Unito 166
RU - Federazione Russa 158
AR - Argentina 127
BD - Bangladesh 75
IN - India 75
EC - Ecuador 58
MX - Messico 57
FR - Francia 48
EU - Europa 46
CI - Costa d'Avorio 45
IQ - Iraq 45
JP - Giappone 39
PL - Polonia 39
CO - Colombia 32
BE - Belgio 28
ES - Italia 27
UZ - Uzbekistan 27
ID - Indonesia 25
VE - Venezuela 25
PY - Paraguay 23
MA - Marocco 22
AT - Austria 21
IR - Iran 21
EG - Egitto 20
PK - Pakistan 20
LT - Lituania 18
CL - Cile 17
SA - Arabia Saudita 17
CZ - Repubblica Ceca 14
KR - Corea 14
AE - Emirati Arabi Uniti 13
PE - Perù 12
RO - Romania 12
KE - Kenya 11
AU - Australia 10
JO - Giordania 10
KZ - Kazakistan 10
TN - Tunisia 10
CR - Costa Rica 9
UY - Uruguay 8
AZ - Azerbaigian 7
AL - Albania 6
BG - Bulgaria 6
BO - Bolivia 6
HU - Ungheria 6
IL - Israele 6
JM - Giamaica 6
OM - Oman 6
PH - Filippine 6
RS - Serbia 6
AM - Armenia 5
DZ - Algeria 5
HN - Honduras 5
LB - Libano 5
NP - Nepal 5
PA - Panama 5
TT - Trinidad e Tobago 5
BH - Bahrain 4
CG - Congo 4
DO - Repubblica Dominicana 4
SK - Slovacchia (Repubblica Slovacca) 4
AF - Afghanistan, Repubblica islamica di 3
BY - Bielorussia 3
GR - Grecia 3
LU - Lussemburgo 3
LV - Lettonia 3
MD - Moldavia 3
MY - Malesia 3
NG - Nigeria 3
SY - Repubblica araba siriana 3
BA - Bosnia-Erzegovina 2
GA - Gabon 2
GT - Guatemala 2
HR - Croazia 2
KG - Kirghizistan 2
MN - Mongolia 2
NI - Nicaragua 2
QA - Qatar 2
SN - Senegal 2
SR - Suriname 2
SV - El Salvador 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BB - Barbados 1
Totale 28.897
Salva come PNG Salva come JPEG
Città #
Singapore 2.058
Dublin 1.484
Chandler 1.347
Ashburn 1.051
Jacksonville 879
Hong Kong 795
Beijing 719
Santa Clara 685
Izmir 616
Dearborn 604
Nanjing 528
Boardman 468
San Mateo 423
Princeton 391
Johannesburg 343
Dallas 293
Wilmington 241
Ho Chi Minh City 233
Los Angeles 203
Parma 177
Shenyang 172
Shanghai 171
Ann Arbor 154
Nanchang 152
Helsinki 150
Toronto 139
Hanoi 136
Columbus 134
Hebei 124
Moscow 109
São Paulo 109
Tianjin 107
Kunming 103
Munich 101
Hefei 94
Jinan 91
Seattle 86
Jiaxing 85
Changsha 83
Grafing 73
New York 69
Norwalk 65
Buffalo 60
Guangzhou 51
Turku 44
Abidjan 43
Bremen 43
Kocaeli 42
Brooklyn 41
Houston 39
Rio de Janeiro 36
Frankfurt am Main 35
Tokyo 34
Des Moines 32
Düsseldorf 32
Hangzhou 32
Woodbridge 32
Belo Horizonte 30
Boston 30
Warsaw 30
London 29
Zhengzhou 29
Montreal 27
The Dalles 27
Brussels 25
Council Bluffs 25
Porto Alegre 24
Tashkent 24
Haiphong 23
Guayaquil 22
Phoenix 22
Rockville 22
Brasília 21
Chicago 21
Guarulhos 21
Stockholm 21
Borås 20
Da Nang 20
Chennai 19
Baghdad 18
Biên Hòa 18
San Francisco 18
Fremont 17
Hải Dương 17
Ankara 16
Denver 16
Dhaka 16
Mexico City 16
Salvador 16
Washington 16
Atlanta 15
Curitiba 15
Ningbo 15
Pune 15
Vienna 15
Campinas 14
Fuzhou 14
Nuremberg 14
Orem 14
Quito 14
Totale 17.502
Salva come PNG Salva come JPEG
Nome #
Alginate containing formulations: are they all the same? 156
[Effect of cimetidine on acute experimental pancreatitis in the rat]. 151
W1079 Curcumin Vs Domperidon in Functional Dyspepsia: Better the Prokinetic or An Agonist of Vanilloid Receptor? 145
Dysphagia and clinical outcome after laparoscopic Nissen or Rossetti fundoplication: sequential prospective study 137
Antacids and alginates in the treatment of gastroesophageal reflux disease: how do they work and how much are they clinically useful? 136
Myths and misconceptions about chronic constipation 135
[Protective effect of ranitidine in acute experimental pancreatitis in the rat]. 132
Caustic injury of the upper gastrointestinal tract: A comprehensive review 131
Assembled delivery modules for clarithromycin release in Helicobacter Pylori therapy 129
T1082 Eradication Rate of Helicobacter pylori in Immigrant Patients Compared to Italian Patients: Results of a Clinical Trial 129
Gastric function assessed by Gastropanel in very old patients (over 80 years old) and appropriateness of PPIs administration 127
Corrosive Esophageal Strictures in Children:. Outcomes after Timely or Delayed Dilatation. 124
ACID SUPPRESSION THERAPY: WHERE DO WE FROM HERE? 123
P.1.193: MESALAMINE FOR THE MANAGEMENT OF PATIENTS WITH UNCOMPLICATED DIVERTICULAR DISEASE (SUDD): A 24 MONTHS PROSPECTIVE FOLLOW-UP STUDY 123
P.02.8: Chronic Atrophic Gastritis is Related with an Increased Risk for Cardiovascular Diseases, Assessed by Homocysteine Serum Levels Determination 122
Acid suppression in Barrett's esophagus: why and how? 121
P.29 USEFULNESS OF NON INVASIVE TEST (GASTROPANEL) FOR SCREENING OF ATROPHIC GASTRITIS IN PATIENTS WITH AUTOIMMUNE THYROID DISEASE 121
P.1.288: PEPSINOGEN I, II, RATIO, AND G-17 IN PATIENTS WITH ESOPHAGITIS AND PATIENTS WITH EXTRA-ESOPHAGEAL MANIFESTATIONS OF GERD 120
Caustic ingestion in children: is endoscopy always indicated? A perspective from a Sierra Leone experience 119
Gastrin 17 in Singling Out Patients with Different Patterns of Refluxate: A Pilot Study Using Impedance-pH as Reference Standard 118
PA.28 SERUM PEPSINOGEN I AS NON INVASIVE MARKER OF GASTRIC ACID SECRETION 118
M1261 Recurrence of Diverticulitis in Patients With Symptomatic Uncomplicated Diverticular Disease (SUDD) Treated Cyclically With Mesalamine: Result of a Follow-up Study 117
Usefulness of Serum Pepsinogens to Identify Chronic Atrophic Gastritis 116
ASSESSMENT OF SYMPTOMS IN PATIENTS WITH SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE (SUDD) 116
Evaluation of clinical outcome after laparoscopic antireflux surgery in clinical practice: still a controversial issue. 116
T1979 Pepsinogen II As Marker of Inflammation in H.P Infection and in NSAIDs Damage 116
Corrosive oesophageal strictures in children: outcomes after timely or delayed dilatation 115
Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety 115
FLOTATION OF DOSAGE FORMS AND DEVICES FOR SITE SPECIFIC THERAPY 115
T1651 The Natural History of Gastric Ulcer: A Twenty-Four Years Clinical-Endoscopical Follow-Up 115
PA.6 GASTRIN-17 (G-17): A SEROLOGICAL BIO-MARKER FOR DIAGNOSIS OF GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) 115
P.01.14: Overweight and Obesity as Risk Factors for Gerd Outcome: A 10 Years Study on a Gerd Population of 365 Patients 115
"RESCUE" THERAPIES FOR THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION 114
P.02.18: Non Invasive Diagnosis of Upper Gi Diseases in a Primary Care Setting: A Study on 1,900 Patients 114
A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation 113
OC3.07.1 CURCUMIN VS DOMPERIDON IN FUNCTIONAL DYSPEPSIA: BETTER THE PROKINETIC OR AN AGONIST OF VANILLOID RECEPTOR? 113
P.05.11 CLINICAL USEFULNESS OF LACTOSE-RESTRICTED DIET IN POSITIVE QUICK LACTASE TEST PATIENTS: PROSPECTIVE 4 MONTHS STUDY 113
EFFECTS OF SOME ANTIULCER DRUGS ON ACUTE EXPERIMENTAL PANCREATITIS IN THE RAT. 112
Pepsinogen I, II, Ratio, and G-17 in Patients With Esophagitis and Patients With Extra-Esophageal Manifestations of GERD 112
Is the interval between the first and the second H.P. eradication therapy relevant for the success of the cure? A comparison between one week, one month and one year 112
Antacids and alginate-containing preparations: what is their mechanism of action and their place in the management of GERD? 111
P.02.2: Improvement of Symptoms in Patients Affected by Chronic Athrophic Gastritis: A 2 Years Prospective Study by using L-Cysteine (Acetium™) 111
M1141 Diagnostic Accuracy of Serum Pepsinogens and Gastrin to Follow-up Helicobacter pylori Infection: A Pilot Study 110
Action of MDL 646, a new synthetic prostaglandin, on gastric acid secretion of some experimental animals. 109
M1260 Effect of Cyclically Long-Term Treatment With Mesalamine in Patients With Symptomatic Uncomplicated Diverticular Disease (SUDD): A 5 Years Follow-up Study 109
P.01.7: Efficacy of PPIS and H-2 Blockers Therapy on Acid Suppression Assessed by Gastrin-17 and Pepsinogen I Serum Levels Determination in Gerd Patients 108
Antidiarroici ed Antispastici 107
ADVANCES IN GI PHARMACOLOGY AND THERAPEUTICS 107
[Cerebral homovanillic acid and audiogenic stress in the rat: effect of Cannabis resin]. 107
Distinct receptors mediate gastrin-releasing peptide and neuromedin beta-induced delay of gastric of liquids in rats. 107
P.02.9: Prevalence of Atrophic Gastritis in General Population: A Gastropanel®-Based Study, Compared with Olga Histological Classification 107
Does the Learning Phase influence the late outcome of patients with gastroesophageal reflux disease after laparoscopic fundoplication? 106
Recovery of Gastric Function in Chronic Atrophic Gastritis By Using L-Cysteine: A 3 Years Study 106
Sa1862 Are All Patients With Histological Diagnosis of Atrophic Gastritis Really At Risk of Developing Gastric Cancer? Assessment of Gastric Acid Production by Correlation Between Maximal Acid Output and Pepsinogen I 106
OC.18.1 ARE ALL PATIENTS WITH HISTOLOGICAL DIAGNOSIS OF ATROPHIC GASTRITIS REALLY AT RISK OF DEVELOPING GASTRIC CANCER? ASSESSMENT OF GASTRIC ACID PRODUCTION BY CORRELATION BETWEEN MAXIMAL ACID OUTPUT AND PEPSINOGEN I 106
Can gangrenous cholecystitis be prevented?: a plea against a "wait and see" attitude. 105
Acid-lowering drugs in the treatment of gastroesophageal reflux disease: an overview. 105
Antacids in gastroesophageal reflux disease. 105
Esomeprazole immediate release tablets: Gastric mucosa ex vivo permeation, absorption and antisecretory activity in conscious rats 105
The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel 104
P.02.1: Individual Assessment of Gastric Acid Production by Means of a Non-Invasive Test: Relationship Between Maximal Acid Output and Serum Pepsinogen I Levels in Patients with Different Upper GI Diseases 104
M1262 Baseline Symptoms in Patients With Symptomatic Uncomplicated Diverticular Disease (SUDD) 104
Antacid protection of the gastric mucosa: an overview. 103
P.10 “GASTROPANEL TEST” IN THE CLINICAL OUTCOME OF GERD: PROSPECTIVE SIX MONTHS CLINICAL STUDY 103
Spasmolytic effect of octylonium bromide on gastrointestinal motility in vitro. 102
In vitro comparison of medicinal products based on alginic acid claimed to protect the esophagus wall and physically prevent acid reflux 102
Non Invasive Diagnosis of Upper GI Diseases in a Primary Care Setting: A Study on 1,900 Patients 102
Dysphagia aortica: a neglected symptom of aortoesophageal fistula 102
Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle 101
Action of caerulein on gastric emptying of the conscious rat. 101
Involvement of the P2X7 purinergic receptor in colonic motor dysfunction associated with bowel inflammation in rats 101
Environmental factors (divorce, job changing, night shift change): critical role in IBS outcome. A study on 110 consecutive patients 101
A simple method for the measurement of human gastric emptying: standardization of operative parameters. 100
P.01.11: Gastrin 17 in Singling out Patients with Different Pattern of Gastroesophageal Reflux: A Pilot Study using PH-Impedance as Reference Standard 100
OC.07.3 RECOVERY OF GASTRIC FUNCTION AFTER ACETIUM® ADMINISTRATION: A 2 YEAR PROSPECTIVE STUDY IN PATIENTS WITH CHRONIC, ATROPHIC, BODY GASTRITIS 100
P.02.7: The Branded Proton Pump Inhibitors (PPIS) Increase Levels of Gastrin 17 (G-17) More than the Generic Ones in Dyspeptic Patients from an Italian Primary Care Population 100
P.07.2: Natural History of Symptomatic Uncomplicated Diverticular Disease: A 13-Year Prospective Study 99
P.12.12 INTERMITTENT VERSUS EVERY-DAY MESALAZINE THERAPY IN PREVENTING COMPLICATIONS OF DIVERTICULAR DISEASE OF THE COLON: A LONG-TERM FOLLOW-UP STUDY 99
OC.09.2: Appropriateness of PPI Administration in the Elderly: Evaluation of Acid Secretion and Atrophic Gastritis by Means of a Non-Invasive Test 99
Natural history of gastric ulcer in a 25-years follow-up: role of helicobacter pylori infection and nonsteroidal anti-inflammatory drugs 99
P.04.11 A NEW APPROACH TO DETECTION OF NON-RESPONDER PATIENTS IN GERD BY NON-INVASIVE MARKERS 98
Sa1988 Recovery of Gastric Function After Helicobacter pylori Eradication and Acetium Administration: A 6 Years Study in Atrophic Gastritis Subjects 98
Monitoring risk factors fot the onset of esophagitis in a long 15-years follow-up 98
Corrosive esophageal injuries in children. A shortlived experience in Sierra Leone 97
[Modalities and diagnostic criteria in esophageal ph monitoring]. 97
Prokinetics in the treatment of gastro-oesophageal reflux disease. International symposium. Paris, France, 5 September 1996. 97
Comparing tapentadol to oxycodone/naloxone combination: building castles in the air. 97
Italian consensus conference for colonic diverticulosis and diverticular disease 97
Quantification of serum levels of pepsinogens and gastrin to assess eradication of Helicobacter pylori 96
P.04.9 DIAGNOSIS OF CHRONIC ATROPHIC GASTRITIS IN PRIMARY CARE SETTING BY MEANS OF GASTROPANEL®: A POPULATION STUDY ON 10,000 CONSECUTIVE PATIENTS 96
Serum Pepsinogen II as a non-invasive marker for diagnosis of Helicobacter pylori infection: a prospective study in a cohort of dyspeptic patients 96
Commentary: towards an effective and safe treatment of small intestine bacterial overgrowth 95
Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy 95
Non invasive diagnosis of upper GI disease in a primary care setting: A study on 1900 patients 95
Efficacy and safety of piroxicam revisited. A global meta-analysis of randomised clinical trials 94
P.09.23 OVERLAP OF THREE PATHOLOGICAL CONDITIONS (HELICOBACTER PYLORI INFECTION, YELLOW STOMACH AND LACTOSE INTOLERANCE) IN PATIENTS WITH GASTROINTESTINAL DISORDERS 94
Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study 94
P.09.1 RECOVERY OF GASTRIC FUNCTION AFTER HELICOBACTER PYLORI ERADICATION AND ACETIUM ADMINISTRATION: A 6 YEARS STUDY IN ATROPHIC GASTRITIS SUBJECTS 94
P.1.325: USEFULNESS OF SERUM PEPSINOGENS TO IDENTIFY CHRONIC ATROP H IC GASTRITIS 93
Poor effectiveness of PPIs in Non-Erosive Reflux Disease: the truth in the end! 93
Totale 10.968
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.871
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.871
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021758 0 0 0 0 0 8 64 3 441 57 162 23
2021/20221.704 17 4 1 66 61 77 125 308 72 227 201 545
2022/20234.813 671 395 260 341 345 533 20 284 1.779 15 131 39
2023/20241.675 81 177 40 72 177 371 43 117 56 130 178 233
2024/20256.282 87 439 506 250 691 540 109 164 1.056 686 574 1.180
2025/20267.025 1.113 1.252 1.332 1.106 1.910 312 0 0 0 0 0 0
Totale 29.065